연구성과로 돌아가기
JCR 2023 저널 목록 (1303 / 2065)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Journal Name | Publisher | ISSN | eISSN | Edition | WoS Category | Total Citation | JIF | JIF Quartile | 상위 JCR(%) | JIF % | JIF Rank | 5-Year JIF | 5-Year Quartile | JIF w/o Self-Cites | Immediacy Index | JCI | JCI Rank | JCI Quartile | JCI Percentile | Eigenfactor Score | Normalized Eigenfactor | Article Influence Score | AIS Quartile | Citable Items | Articles in Citable Items (%) | Cited Half-Life | Citing Half-Life | Total Articles | Citable OA (%) | 수집시기 | 바로가기 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ANTI-CANCER DRUGS | LIPPINCOTT WILLIAMS & WILKINS | 0959-4973 | 1473-5741 | SCIE | PHARMACOLOGY & PHARMACY | 4,075 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 1.9 | Q3 | 1.8 | 0.7 | 0.63 | 189/354 | Q3 | 46.75 | 0.002 | 0.527 | 0.365 | Q3 | 142 | 86.6% | 8.4 | 5.7 | 123 | 18.9% | 2025-03-24 17:36:25 | 바로가기 |
| BIOMEDICAL CHROMATOGRAPHY | WILEY | 0269-3879 | 1099-0801 | SCIE | PHARMACOLOGY & PHARMACY | 5,277 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 1.8 | Q3 | 1.6 | 0.5 | 0.44 | 258/354 | Q3 | 27.26 | 0.003 | 0.676 | 0.275 | Q4 | 235 | 97.0% | 6.4 | 6.3 | 228 | 3.3% | 2025-03-24 17:36:22 | 바로가기 |
| CLINICAL NEUROLOGY AND NEUROSURGERY | ELSEVIER | 0303-8467 | 1872-6968 | SCIE | CLINICAL NEUROLOGY | 8,737 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 1.8 | Q4 | 1.7 | 0.3 | 0.65 | 160/281 | Q3 | 43.24 | 0.010 | 2.239 | 0.544 | Q3 | 376 | 85.9% | 6.4 | 7.5 | 323 | 7.3% | 2025-03-24 17:00:23 | 바로가기 |
| Current Alzheimer Research | BENTHAM SCIENCE PUBL LTD | 1567-2050 | 1875-5828 | SCIE | CLINICAL NEUROLOGY | 4,776 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 2.9 | Q2 | 1.7 | 0.4 | 0.43 | 220/281 | Q4 | 21.89 | 0.003 | 0.629 | 0.645 | Q3 | 55 | 70.9% | 7.9 | 8.3 | 39 | 3.0% | 2025-03-24 17:00:27 | 바로가기 |
| Current Treatment Options in Neurology | CURRENT MEDICINE GROUP | 1092-8480 | 1534-3138 | SCIE | CLINICAL NEUROLOGY | 1,487 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 2.4 | Q3 | 1.8 | 0.3 | 0.37 | 231/281 | Q4 | 17.97 | 0.002 | 0.335 | 0.768 | Q3 | 32 | 0.0% | 7.2 | 7.1 | 0 | 15.6% | 2025-03-24 17:00:37 | 바로가기 |
| Epilepsy & Behavior Reports | ELSEVIER SCIENCE INC | N/A | 2589-9864 | ESCI | CLINICAL NEUROLOGY | 398 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | N/A | N/A | 1.8 | 0.3 | 0.47 | 205/281 | Q3 | 27.22 | 0.001 | 0.225 | N/A | N/A | 55 | 92.7% | 2.5 | 7.1 | 51 | 99.5% | 2025-03-24 17:00:43 | 바로가기 |
| Expert Review of Pharmacoeconomics & Outcomes Research | TAYLOR & FRANCIS LTD | 1473-7167 | 1744-8379 | SCIE | PHARMACOLOGY & PHARMACY | 2,470 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 2.2 | Q3 | 1.6 | 0.3 | 0.57 | 210/354 | Q3 | 40.82 | 0.002 | 0.531 | 0.650 | Q2 | 113 | 75.2% | 7.3 | 5.6 | 85 | 27.6% | 2025-03-24 17:36:31 | 바로가기 |
| Exploratory Research in Clinical and Social Pharmacy | ELSEVIER | N/A | 2667-2766 | ESCI | PHARMACOLOGY & PHARMACY | 389 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 1.8 | Q3 | 1.6 | 0.4 | 0.45 | 254/354 | Q3 | 28.39 | 0.001 | 0.150 | 0.471 | Q3 | 181 | 90.1% | 1.8 | 5.9 | 163 | 94.4% | 2025-03-24 17:36:46 | 바로가기 |
| HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL | WILEY | 0885-6222 | 1099-1077 | SCIE | CLINICAL NEUROLOGY | 1,868 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 1.7 | Q4 | 1.8 | 0.2 | 0.50 | 197/281 | Q3 | 30.07 | 0.001 | 0.155 | 0.488 | Q4 | 22 | 72.7% | 11.8 | 8.8 | 16 | 27.5% | 2025-03-24 17:00:35 | 바로가기 |
| HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL | WILEY | 0885-6222 | 1099-1077 | SCIE | PHARMACOLOGY & PHARMACY | 1,868 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 1.7 | Q3 | 1.8 | 0.2 | 0.50 | 235/354 | Q3 | 33.76 | 0.001 | 0.155 | 0.488 | Q3 | 22 | 72.7% | 11.8 | 8.8 | 16 | 27.5% | 2025-03-24 17:36:35 | 바로가기 |
| Iranian Journal of Pharmaceutical Research | BRIEFLAND | 1735-0328 | 1726-6890 | SCIE | PHARMACOLOGY & PHARMACY | 3,914 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 2.0 | Q3 | 1.8 | 0.1 | 0.43 | 262/354 | Q3 | 26.13 | 0.002 | 0.464 | 0.310 | Q4 | 43 | 97.7% | 7.0 | 7.3 | 42 | 46.0% | 2025-03-24 17:36:26 | 바로가기 |
| JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY | TAYLOR & FRANCIS INC | 1380-3395 | 1744-411X | SCIE | CLINICAL NEUROLOGY | 5,207 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 2.2 | Q3 | 1.7 | 0.3 | 0.61 | 175/281 | Q3 | 37.90 | 0.002 | 0.455 | 0.711 | Q3 | 64 | 92.2% | 14.8 | 11.4 | 59 | 14.9% | 2025-03-24 17:00:27 | 바로가기 |
| JOURNAL OF SPINAL CORD MEDICINE | TAYLOR & FRANCIS LTD | 1079-0268 | 2045-7723 | SCIE | CLINICAL NEUROLOGY | 3,691 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 2.0 | Q3 | 1.6 | 0.3 | 0.53 | 191/281 | Q3 | 32.21 | 0.003 | 0.715 | 0.589 | Q3 | 93 | 89.2% | 8.3 | 9.2 | 83 | 14.4% | 2025-03-24 17:00:29 | 바로가기 |
| Neurotrauma Reports | MARY ANN LIEBERT, INC | N/A | 2689-288X | ESCI | CLINICAL NEUROLOGY | 316 | 1.8 | Q3 | 67.7 | 32.3 | 190/280 | 2.1 | Q3 | 1.7 | 0.4 | 0.47 | 205/281 | Q3 | 27.22 | 0.001 | 0.161 | 0.651 | Q3 | 79 | 97.5% | 2.4 | 8.3 | 77 | 100.0% | 2025-03-24 17:00:43 | 바로가기 |
| Pharmaceutical Patent Analyst | TAYLOR & FRANCIS LTD | 2046-8954 | 2046-8962 | ESCI | PHARMACOLOGY & PHARMACY | 253 | 1.8 | Q3 | 67.7 | 32.3 | 240/354 | 1.8 | Q3 | 1.7 | 0.4 | 0.29 | 293/354 | Q4 | 17.37 | 0.000 | 0.039 | 0.338 | Q4 | 13 | 61.5% | 7.0 | 5.4 | 8 | 0.0% | 2025-03-24 17:36:47 | 바로가기 |
페이지 이동: